Press releases
- AbCellera Reports Q1 2024 Business Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.53 |
---|---|
High | 3.53 |
Low | 3.53 |
Bid | 3.56 |
Offer | 3.59 |
Previous close | 3.53 |
Average volume | 0.00 |
---|---|
Shares outstanding | 294.05m |
Free float | 211.77m |
P/E (TTM) | -- |
Market cap | 1.13bn USD |
EPS (TTM) | -0.5056 USD |
Data delayed at least 15 minutes, as of May 22 2024 07:14 BST.
More ▼